Clinical trials
Lymphoma clinical trials
Cancer of the lymphatic system, part of the body’s immune defenses. We’re tracking 1,373 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07126678Recruiting
Zanubrutinib, Bendamustine, and Obinutuzumab for advanced follicular lymphoma
This trial tests a 3-drug combination (Zanubrutinib, Bendamustine, and Obinutuzumab) for people with advanced follicular lymphoma who have not had treatment before. The goal is to see if a fixed-duration treatment plan can improve outcomes.
Nanjing, JiangsuAges 18–75 - NCT07128641RecruitingPhase 2
Odronextamab for early follicular lymphoma without prior treatment
This trial tests a new immunotherapy drug, odronextamab, for people with slow-growing follicular lymphoma that hasn't been treated yet and isn't causing big problems. It aims to see if the drug can control the cancer with fewer side effects.
Boston, MassachusettsAges 18 years+ - NCT07138547RecruitingPhase 1/Phase 2
Eliglustat plus CD30 immunotherapy for CD30+ lymphoma
This trial tests a combination of two medicines (eliglustat and a CD30-targeted immunotherapy) for people with a type of lymphoma that has a specific marker called CD30. It aims to see if this combination can help when standard treatments have already been used.
Beijing, Beijing MunicipalityAges 18–75 - NCT07147621Recruiting
Chemotherapy and thinking changes in blood cancer treatment
This study looks at whether chemotherapy for blood cancers like leukemia and lymphoma can affect thinking, memory, or concentration. It compares patients to a close family member or friend to see if any changes are related to the treatment.
Angers, Maine et LoireAges 18 years+ - NCT07164560RecruitingPhase 1
CAR-NK cell therapy for relapsed T-cell lymphoma
This trial tests a new treatment using immune cells (CAR-NK) made from donated cord blood. These cells are designed to find and attack T-cell lymphoma that has come back or not responded to other treatments. The goal is to see if this approach is safe and effective.
Hangzhou, ZhejiangAges 18–75 - NCT07188090RecruitingPhase 2
Mozobil for stem cell transplant study
This study tests if adding Mozobil (a drug that helps release stem cells) before stem cell transplant can improve outcomes for people with multiple myeloma, Hodgkin's lymphoma, or non-Hodgkin lymphoma. If you are eligible, you will receive Mozobil along with standard stem cell mobilization medicines.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07189065RecruitingPhase 2
Rocbrutinib for relapsed or refractory non-GCB DLBCL
This trial tests a new targeted therapy, Rocbrutinib, for a specific type of aggressive B-cell lymphoma (non-GCB DLBCL) that has not responded to or returned after two or more prior treatments. It aims to see if Rocbrutinib can help people who have few other options.
Hefei, AnhuiAges 18 years+ - NCT07198230Recruiting
DEB-TACE therapy for large lymphoma tumors that have returned or not responded
This trial tests a second-line treatment called DEB-TACE (tiny beads filled with chemo placed directly into the tumor's blood supply) for people with large, hard-to-treat lymphoma tumors that have come back or not responded to other therapies. If you have at least one big tumor with good blood supply and have tolerated doxorubicin chemo before, this might be an option.
Fuzhou, FujianAges 18–75 - NCT07211048Recruiting
Gene therapy for B-cell lymphoma that hasn't responded to standard treatment
This trial tests a new gene therapy that re-engineers your own immune cells to attack CD19-positive lymphoma. It is for people whose B-cell lymphoma has come back or not responded to at least two standard treatments.
Hefei, AnhuiAges 18 years+ - NCT07218510RecruitingPhase 2
Venetoclax, obinutuzumab, then epcoritamab for untreated CLL/SLL
This trial tests a new combination of three drugs for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had treatment yet. The goal is to see if this approach helps control the disease with fewer side effects.
Duarte, CaliforniaAges 18 years+ - NCT07220993RecruitingPhase 1
Modified immune cells for aggressive T-cell cancers
This trial tests a new treatment using specially engineered immune cells (CAR T cells) from a past stem cell donor to attack cancer cells in people with certain types of T-cell cancers that have returned after a stem cell transplant. The goal is to see if this treatment can lead to remission so a second stem cell transplant can be done.
Houston, TexasAges Up to 75 years - NCT07222345Recruiting
High-intensity interval training for Hodgkin lymphoma survivors
This study tests if a high-intensity interval training (HIIT) program is safe and doable for young people who have finished treatment for Hodgkin lymphoma. It might help you regain fitness and strength after recovery.
Memphis, TennesseeAges 10–25 - NCT07222631RecruitingPhase 1/Phase 2
Study of SB-4826 for advanced solid tumors or lymphomas
This trial tests a new drug, SB-4826, for people with advanced solid tumors or certain types of lymphoma that have not responded to standard treatments. The goal is to see if the drug is safe and effective, either alone or with another drug called rituximab.
La Jolla, CaliforniaAges 18 years+ - NCT07231952RecruitingPhase 2
Pirtobrutinib, venetoclax, and rituximab for Waldenstrom's macroglobulinemia
This trial tests a combination of three drugs (pirtobrutinib, venetoclax, and rituximab) for people newly diagnosed with Waldenstrom's macroglobulinemia who have not had treatment before and need therapy for their symptoms.
Boston, MassachusettsAges 18 years+ - NCT07233720Recruiting
Zanubrutinib plus rituximab for first-line marginal zone lymphoma
This trial tests a combination of two targeted drugs (zanubrutinib and rituximab) as a first treatment for marginal zone lymphoma. The goal is to see how well this drug pair works for people who have not received any prior cancer therapy.
Zhengzhou, HenanAges Any age - NCT07246213Recruiting
Childhood cancer survivor research study
This study looks back at the medical records of children and young adults diagnosed with cancer in the last 15 years. It helps researchers understand more about cancer in young people.
YerevanAges birth–21 years - NCT07073833RecruitingPhase 1
IBR900 cell therapy for relapsed/refractory B-cell lymphoma
This trial tests a new cell therapy (IBR900) for people with a type of B-cell lymphoma that has come back or not responded to prior treatments. The therapy uses your own immune cells to target and kill the cancer cells.
Hangzhou, ZhejiangAges 18 years+ - NCT07680933RecruitingPhase 2
Orelabrutinib plus chemo for newly diagnosed DLBCL
This trial tests if adding orelabrutinib (a targeted pill) to standard chemotherapy, with or without a stem cell transplant, works better for people with a new diagnosis of diffuse large B-cell lymphoma. It may help patients who have a higher risk of the lymphoma coming back.
Xuzhou, JiangsuAges 18–80 - NCT07254754RecruitingPhase 2
CAR-T cell therapy for late-relapse aggressive lymphoma
This trial tests a special immune cell therapy (CAR-T cells) for people with a type of aggressive lymphoma that returned more than a year after first treatment. It aims to see if this therapy can help control the cancer again.
A Coruña, A CoruñaAges 18 years+ - NCT07257510Recruiting
Pomalidomide plus two other drugs for untreated Mantle Cell Lymphoma
This trial tests a combination of three drugs (pomalidomide, orelabrutinib, and zuberitamab) in people with Mantle Cell Lymphoma who have not yet received treatment. It aims to see if this combination works better than standard therapy, especially for those with high-risk features.
Beijing, Beijing MunicipalityAges 18–80 - NCT07261163RecruitingPhase 2
Combination therapy for first-line mantle cell lymphoma
This trial tests a combination of three drugs—obinutuzumab, zanubrutinib, and lenalidomide—as a first treatment for mantle cell lymphoma. The goal is to see if this approach is safe and effective for patients who have not had prior therapy.
Tianjin, Tianjin MunicipalityAges 18–80 - NCT07268846Recruiting
Prebiotic supplement before colorectal cancer surgery
This trial tests if taking a postbiotic supplement before surgery for colorectal cancer can improve recovery. It may help patients with adenocarcinoma of the large intestine prepare for their operation.
São Paulo, São PauloAges 18 years+ - NCT07270835RecruitingPhase 4
Zanubrutinib plus rituximab for HLH with B-cell lymphoma
This study tests a combination of two drugs—zanubrutinib and rituximab—to treat HLH that happens in people with B-cell lymphoma. It aims to see if this treatment is safe and works better.
Suzhou, JiangsuAges 14–80 - NCT07270861Recruiting
Study of peripheral T-cell lymphoma outcomes in real-world care
This study is looking at how peripheral T-cell lymphoma (PTCL) behaves and responds to treatment in real-world settings. It includes patients diagnosed over many years to better understand the disease and improve care.
Shanghai, Shanghai MunicipalityAges 18 years+
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lymphoma?
- Yes. Clin2 currently lists 1,373 recruiting lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.